{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:26Z","timestamp":1787020106975,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03749-7","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T09:34:37Z","timestamp":1741858477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical value of systemic immunoinflammatory index in predicting recurrence and metastasis in patients with primary liver cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Yang","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6361-3419","authenticated-orcid":false,"given":"Qiufeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangjie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"3749_CR1","doi-asserted-by":"publisher","first-page":"104295","DOI":"10.1016\/j.cellimm.2021.104295","volume":"361","author":"C Ma","year":"2021","unstructured":"Ma C, Zhang Q, Greten TF. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cell Immunol. 2021;361:104295.","journal-title":"Cell Immunol"},{"key":"3749_CR2","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1111\/liv.15357","volume":"42","author":"C Li","year":"2022","unstructured":"Li C, He WQ. Comparison of primary liver cancer mortality estimates from world health organization, global burden disease and global cancer observatory. Liver Int. 2022;42:2299\u2013316.","journal-title":"Liver Int"},{"key":"3749_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1515\/hsz-2017-0118","volume":"398","author":"T Tu","year":"2017","unstructured":"Tu T, Buhler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem. 2017;398:817\u201337.","journal-title":"Biol Chem"},{"key":"3749_CR4","doi-asserted-by":"crossref","unstructured":"Liang C, He Z, Tao Q, Tang X, Jiang L, Tu X et al. From conversion to resection for unresectable hepatocellular carcinoma: A review of the latest strategies. J Clin Med. 2023; 12.","DOI":"10.3390\/jcm12247665"},{"key":"3749_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12957-021-02401-4","volume":"19","author":"Z Shao","year":"2021","unstructured":"Shao Z, Liu X, Peng C, Wang L, Xu D. Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review. World J Surg Oncol. 2021;19:293.","journal-title":"World J Surg Oncol"},{"key":"3749_CR6","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.21037\/tcr-22-816","volume":"11","author":"Y Yu","year":"2022","unstructured":"Yu Y, Fu J, Xia P, Chu C. A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer. Transl Cancer Res. 2022;11:1297\u2013308.","journal-title":"Transl Cancer Res"},{"key":"3749_CR7","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.2174\/1389557522666220218124816","volume":"22","author":"K Zhao","year":"2022","unstructured":"Zhao K, Zhou X, Xiao Y, Wang Y, Wen L. Research progress in Alpha-fetoprotein-induced immunosuppression of liver Cancer. Mini Rev Med Chem. 2022;22:2237\u201343.","journal-title":"Mini Rev Med Chem"},{"key":"3749_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.14639\/0392-100X-N1665","volume":"42","author":"A Kars","year":"2022","unstructured":"Kars A, Sahin A, Kilic K, Sakat MS, Bilen A. Systemic immune inflammation index in differentiated thyroid cancers. Acta Otorhinolaryngol Ital. 2022;42:150\u20134.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"3749_CR9","doi-asserted-by":"publisher","first-page":"e23486","DOI":"10.1097\/MD.0000000000023486","volume":"99","author":"L Wei","year":"2020","unstructured":"Wei L, Xie H, Yan P. Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis. Med (Baltim). 2020;99:e23486.","journal-title":"Med (Baltim)"},{"key":"3749_CR10","doi-asserted-by":"crossref","unstructured":"Bi Q, Wu JY, Qiu XM, Zhang JD, Sun ZJ, Wang W. Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis. J Immunol Res. 2022;2022:3128933.","DOI":"10.1155\/2022\/3128933"},{"key":"3749_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.it.2021.11.009","volume":"43","author":"K Mehla","year":"2022","unstructured":"Mehla K, Hollingsworth MA. Inflammatory and immune effects on tumor progression. Trends Immunol. 2022;43:93\u20135.","journal-title":"Trends Immunol"},{"key":"3749_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/coa.13689","volume":"46","author":"Z Li","year":"2021","unstructured":"Li Z, Qu Y, Yang Y, An W, Li S, Wang B, et al. Prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index in patients with laryngeal squamous cell carcinoma. Clin Otolaryngol. 2021;46:395\u2013405.","journal-title":"Clin Otolaryngol"},{"key":"3749_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/fcell.2020.00788","volume":"8","author":"J Zhang","year":"2020","unstructured":"Zhang J, Ji C, Li W, Mao Z, Shi Y, Shi H, et al. Tumor-Educated neutrophils activate mesenchymal stem cells to promote gastric Cancer growth and metastasis. Front Cell Dev Biol. 2020;8:788.","journal-title":"Front Cell Dev Biol"},{"key":"3749_CR14","doi-asserted-by":"crossref","unstructured":"Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci 2022; 23.","DOI":"10.3390\/ijms23073636"},{"key":"3749_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12957-020-01974-w","volume":"18","author":"Y Ji","year":"2020","unstructured":"Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Oncol. 2020;18:197.","journal-title":"World J Surg Oncol"},{"key":"3749_CR16","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00421-021-04668-7","volume":"121","author":"D Walzik","year":"2021","unstructured":"Walzik D, Joisten N, Zacher J, Zimmer P. Transferring clinically established immune inflammation markers into exercise physiology: focus on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index. Eur J Appl Physiol. 2021;121:1803\u201314.","journal-title":"Eur J Appl Physiol"},{"key":"3749_CR17","doi-asserted-by":"crossref","unstructured":"Fu H, Zheng J, Cai J, Zeng K, Yao J, Chen L et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients after liver transplantation for hepatocellular carcinoma within Hangzhou criteria. Cell Physiol Biochem. 2018;47:293-301.","DOI":"10.1159\/000489807"},{"key":"3749_CR18","doi-asserted-by":"crossref","unstructured":"Yen CC, Yen CJ, Shan YS, Lin YJ, Liu IT, Huang HY et al. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification. Histopathology. 2021;79:556\u2009\u2212\u200972.","DOI":"10.1111\/his.14384"},{"key":"3749_CR19","doi-asserted-by":"crossref","unstructured":"Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review. Int J Mol Sci 2021; 22.","DOI":"10.3390\/ijms22115801"},{"key":"3749_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2020.02.003","volume":"477","author":"Y Ge","year":"2020","unstructured":"Ge Y, Mu W, Ba Q, Li J, Jiang Y, Xia Q, et al. Hepatocellular carcinoma-derived exosomes in organotropic metastasis, recurrence and early diagnosis application. Cancer Lett. 2020;477:41\u20138.","journal-title":"Cancer Lett"},{"key":"3749_CR21","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.3748\/wjg.v28.i46.6433","volume":"28","author":"ZS Niu","year":"2022","unstructured":"Niu ZS, Wang WH, Niu XJ. Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma. World J Gastroenterol. 2022;28:6433\u201377.","journal-title":"World J Gastroenterol"},{"key":"3749_CR22","doi-asserted-by":"crossref","unstructured":"Zhang S, Zhao G, Dong H. Effect of Radiofrequency Ablation with Interventional Therapy of Hepatic Artery on the Recurrence of Primary Liver Cancer and the Analysis of Influencing Factors. J Oncol. 2021;2021:3392433.","DOI":"10.1155\/2021\/3392433"},{"key":"3749_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2217\/imt-2022-0133","volume":"14","author":"BW Tian","year":"2022","unstructured":"Tian BW, Yang YF, Yang CC, Yan LJ, Ding ZN, Liu H, et al. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy. 2022;14:1481\u201396.","journal-title":"Immunotherapy"},{"key":"3749_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10654-021-00752-6","volume":"36","author":"TH Nost","year":"2021","unstructured":"Nost TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK biobank. Eur J Epidemiol. 2021;36:841\u20138.","journal-title":"Eur J Epidemiol"},{"key":"3749_CR25","doi-asserted-by":"publisher","first-page":"537140","DOI":"10.3389\/fonc.2021.537140","volume":"11","author":"Y Qiu","year":"2021","unstructured":"Qiu Y, Zhang Z, Chen Y. Prognostic value of pretreatment systemic Immune-Inflammation index in gastric cancer: A Meta-Analysis. Front Oncol. 2021;11:537140.","journal-title":"Front Oncol"},{"key":"3749_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/s41416-022-01767-w","volume":"126","author":"SH Jung","year":"2022","unstructured":"Jung SH, Hao J, Shivakumar M, Nam Y, Kim J, Kim MJ, et al. Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index. Br J Cancer. 2022;126:1539\u201347.","journal-title":"Br J Cancer"},{"key":"3749_CR27","first-page":"1302","volume":"25","author":"Q Wang","year":"2021","unstructured":"Wang Q, Zhu SR, Huang XP, Liu XQ, Liu JB, Tian G. Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25:1302\u201310.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3749_CR28","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1080\/07853890.2021.1991591","volume":"53","author":"X Li","year":"2021","unstructured":"Li X, Gu L, Chen Y, Chong Y, Wang X, Guo P, et al. Systemic immune-inflammation index is a promising non-invasive biomarker for predicting the survival of urinary system cancers: a systematic review and meta-analysis. Ann Med. 2021;53:1827\u201338.","journal-title":"Ann Med"},{"key":"3749_CR29","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1007\/s00432-021-03878-y","volume":"148","author":"L Susok","year":"2022","unstructured":"Susok L, Said S, Reinert D, Mansour R, Scheel CH, Becker JC, et al. The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy. J Cancer Res Clin Oncol. 2022;148:3103\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3749_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s11605-019-04187-z","volume":"24","author":"G Jomrich","year":"2020","unstructured":"Jomrich G, Gruber ES, Winkler D, Hollenstein M, Gnant M, Sahora K, et al. Systemic Immune-Inflammation index (SII) predicts poor survival in pancreatic Cancer patients undergoing resection. J Gastrointest Surg. 2020;24:610\u20138.","journal-title":"J Gastrointest Surg"},{"key":"3749_CR31","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77:1773\u201396.","journal-title":"Hepatology"},{"key":"3749_CR32","doi-asserted-by":"publisher","first-page":"1133308","DOI":"10.3389\/fimmu.2023.1133308","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308.","journal-title":"Front Immunol"},{"key":"3749_CR33","doi-asserted-by":"publisher","first-page":"1180001","DOI":"10.3389\/fimmu.2023.1180001","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhao Y, Li M, Hou H, Jian Z, Li W, et al. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report. Front Immunol. 2023;14:1180001.","journal-title":"Front Immunol"},{"key":"3749_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3233\/CBM-170088","volume":"21","author":"JG Yang","year":"2018","unstructured":"Yang JG, He XF, Huang B, Zhang HA, He YK. Rule of changes in serum GGT levels and GGT\/ALT and AST\/ALT ratios in primary hepatic carcinoma patients with different AFP levels. Cancer Biomark. 2018;21:743\u20136.","journal-title":"Cancer Biomark"},{"key":"3749_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/JHC.S376607","volume":"9","author":"L Gan","year":"2022","unstructured":"Gan L, Ren S, Lang M, Li G, Fang F, Chen L, et al. Predictive value of preoperative serum AFP, CEA, and CA19-9 levels in patients with single small hepatocellular carcinoma: retrospective study. J Hepatocell Carcinoma. 2022;9:799\u2013810.","journal-title":"J Hepatocell Carcinoma"},{"key":"3749_CR36","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.surg.2019.06.005","volume":"166","author":"F Bagante","year":"2019","unstructured":"Bagante F, Spolverato G, Merath K, Weiss M, Alexandrescu S, Marques HP, et al. Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery. 2019;166:983\u201390.","journal-title":"Surgery"},{"key":"3749_CR37","doi-asserted-by":"publisher","first-page":"12077","DOI":"10.2147\/CMAR.S278777","volume":"12","author":"X Yang","year":"2020","unstructured":"Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, et al. The prognostic comparison between hepatocellular carcinoma with portal vein tumor Thrombus and bile duct Cancer Thrombus after liver resection. Cancer Manag Res. 2020;12:12077\u201386.","journal-title":"Cancer Manag Res"},{"key":"3749_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jss.2020.12.001","volume":"261","author":"T Aoki","year":"2021","unstructured":"Aoki T, Matsuda K, Mansour DA, Koizumi T, Goto S, Watanabe M, et al. Narrow-band imaging examination of microvascular architecture of subcapsular hepatic tumors. J Surg Res. 2021;261:51\u20137.","journal-title":"J Surg Res"},{"key":"3749_CR39","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2174\/0929867327999200729151247","volume":"28","author":"W Li","year":"2021","unstructured":"Li W, Liu K, Chen Y, Zhu MY, Li MS. The role of alpha-fetoprotein in hepatocellular carcinoma drug resistance. Curr Med Chem. 2021;28:1126\u201342.","journal-title":"Curr Med Chem"},{"key":"3749_CR40","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00595-005-3077-5","volume":"35","author":"O Morimoto","year":"2005","unstructured":"Morimoto O, Nagano H, Miyamoto A, Fujiwara Y, Kondo M, Yamamoto T, et al. Association between recurrence of hepatocellular carcinoma and \u03b1-fetoprotein messenger RNA levels in peripheral blood. Surg Today. 2005;35:1033\u201341.","journal-title":"Surg Today"},{"key":"3749_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1620\/tjem.2023.J074","volume":"261","author":"S Nakamoto","year":"2023","unstructured":"Nakamoto S, Ohtani Y, Sakamoto I, Hosoda A, Ihara A, Naitoh T. Systemic Immune-Inflammation index predicts tumor recurrence after radical resection for colorectal Cancer. Tohoku J Exp Med. 2023;261:229\u201338.","journal-title":"Tohoku J Exp Med"},{"key":"3749_CR42","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.12998\/wjcc.v9.i21.5754","volume":"9","author":"HY Long","year":"2021","unstructured":"Long HY, Huang TY, Xie XY, Long JT, Liu BX. Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World J Clin Cases. 2021;9:5754\u201368.","journal-title":"World J Clin Cases"},{"key":"3749_CR43","doi-asserted-by":"publisher","first-page":"737","DOI":"10.3349\/ymj.2017.58.4.737","volume":"58","author":"SW Suh","year":"2017","unstructured":"Suh SW, Choi YS. Predictors of micrometastases in patients with Barcelona clinic liver Cancer classification B hepatocellular carcinoma. Yonsei Med J. 2017;58:737\u201342.","journal-title":"Yonsei Med J"},{"key":"3749_CR44","doi-asserted-by":"crossref","unstructured":"Pricop M, Ancusa O, Talpos S, Urechescu H, Bumbu BA. The Predictive Value of Systemic Immune-Inflammation Index and Symptom Severity Score for Sepsis and Systemic Inflammatory Response Syndrome in Odontogenic Infections. J Pers Med. 2022;12:2026.","DOI":"10.3390\/jpm12122026"},{"key":"3749_CR45","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1111\/jcmm.14934","volume":"24","author":"L Chen","year":"2020","unstructured":"Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med. 2020;24:2993\u20133021.","journal-title":"J Cell Mol Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03749-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03749-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03749-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T09:34:43Z","timestamp":1741858483000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03749-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3749"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03749-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments involved in Human participants were approved by the Institutional Review Board of Public Health Clinical Center of Chengdu and conducted according to the Declaration of Helsinki. All patients signed the informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}